Santhera gains on Catena data for DMD

Santhera Pharmaceuticals Holding AG (SIX:SANN) was up CHF0.69 (18%) to CHF4.44 on Tuesday after reporting that once-daily oral Catena idebenone met the primary endpoint vs. placebo in the Phase III DELOS trial to treat Duchenne muscular dystrophy (DMD). Catena improved or delayed the loss of respiratory function as measured by peak expiratory flow from baseline to week 52 vs. placebo (p=0.04). The double-blind, international trial enrolled 65 DMD patients ages 10-18 years who were not using concomitant corticosteroids. Santhera plans to discuss the data with U.S. and European authorities to determine a regulatory pathway for the ubiquinone analog, but could not be reached for a time frame. ...